Novo Nordisk Share Repurchase Program
Analysis based on 6 articles · First reported Apr 07, 2026 · Last updated Apr 27, 2026
The share repurchase program by Novo Nordisk is generally seen as a positive signal to the market, indicating confidence in the company's financial health and a commitment to returning value to shareholders. This action can lead to increased demand for Novo Nordisk shares, potentially supporting its stock price on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk initiated a share repurchase program on February 4, 2026, in accordance with EU regulations. This program is part of an overall plan to repurchase up to DKK 15 billion of its B shares over a 12-month period. Specifically, Novo Nordisk aims to repurchase B shares for up to DKK 3.8 billion between February 4, 2026, and May 4, 2026. As of April 24, 2026, Novo Nordisk has repurchased a total of 13,407,992 B shares, amounting to DKK 3,438,931,195. These repurchases have resulted in Novo Nordisk owning 30,797,791 B shares as treasury shares, representing 0.7% of its share capital. Novo Nordisk is a global healthcare company headquartered in Denmark.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard